

Amendments to the Claims:

This listing of claims will replace all prior versions, and listing, of claims in the application:

1-16. (Cancelled).

17. (Amended) A method for the treatment of ~~type~~ Type II diabetes in a human ~~or non-human mammal~~ which comprises administering an effective, non-toxic amount of a compound which is selected from 5-(4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione, a tautomeric form thereof, and a ~~pharmaceutically acceptable solvate~~ hydrate thereof, to a human ~~or non-human mammal~~ in need thereof, wherein said compound is orally administered one to six times a day to provide a total daily dose of 0.01 mg/kg to 21.4 mg/kg of said compound.

18. (Amended) A method for the treatment of ~~type~~ Type II diabetes in a human ~~or non-human mammal~~ which comprises administering an effective, non-toxic amount of a compound which is selected from a pharmaceutically acceptable salt of 5-(4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione, a tautomeric form of the salt, and a ~~solvate~~ hydrate of the salt, to a human ~~or non-human mammal~~ in need thereof, wherein said compound is orally administered one to six times a day to provide a total daily dose of 0.01 mg/kg to 21.4 mg/kg of said compound.

19. (Amended) A method of treatment according to claim 17, wherein the compound is a ~~pharmaceutically acceptable solvate~~ hydrate of 5-(4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione.

20. (Cancelled).

21. (Previously Presented) A method of treatment according to claim 17, wherein the compound is in the form of an individual isomer.

22. (Previously Presented) A method of treatment according to claim 17, wherein the compound is in the form of a mixture of isomers.

23. (Cancelled).

24. (Amended) A method of treatment according to claim ~~23~~ 17, wherein the compound is administered in the form of a tablet or capsule.

25. (Cancelled).

26. (Amended) A method of treatment according to claim 17, ~~wherein the~~ comprising administering ~~comprises administration of a pharmaceutical composition~~ a tablet or capsule comprising 0.1 mg to 250 mg of the compound.

27. (Amended) A method of treatment according to claim 18, wherein the salt is in the form of a ~~solvate~~ hydrate.

28. (Cancelled).

29. (Previously Presented) A method of treatment according to claim 18, wherein the salt comprises a salt of the thiazolidinedione moiety.

30. (Previously Presented) A method of treatment according to claim 29, wherein the salt comprises a metal salt.

31. (Previously Presented) A method of treatment according to claim 29, wherein the salt comprises an alkali metal salt.

32. (Previously Presented) A method of treatment according to claim 29, wherein the salt comprises a lithium salt.

33. (Previously Presented) A method of treatment according to claim 29, wherein the salt comprises a sodium salt.

34. (Previously Presented) A method of treatment according to claim 29, wherein the salt comprises a potassium salt.

35. (Previously Presented) A method of treatment according to claim 18, wherein the compound is in the form of an individual isomer.

36. (Previously Presented) A method of treatment according to claim 18, wherein the compound is in the form of a mixture of isomers.

37. (Cancelled).

38. (Amended) A method of treatment according to claim ~~37~~ 18, wherein the compound is administered in the form of a tablet or capsule.

39. (Cancelled).

40. (Amended) A method of treatment according to claim 18, ~~wherein the~~ comprising administering ~~comprises administration of a pharmaceutical composition~~ a tablet or capsule comprising 0.1 mg to 250 mg of the compound.

41. (New) A method of treatment according to claim 17, wherein said compound is prepared by a process comprising reducing 5-(4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzylidene)-2,4-thiazolidinedione.

42. (New) A method of treatment according to claim 18, wherein said compound is prepared by a process comprising reducing 5-(4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzylidene)-2,4-thiazolidinedione.